MX373466B - Composiciones que comprenden poblaciones heterogeneas de proteinas recombinantes humanas de factor xa de coagulacion. - Google Patents

Composiciones que comprenden poblaciones heterogeneas de proteinas recombinantes humanas de factor xa de coagulacion.

Info

Publication number
MX373466B
MX373466B MX2016003871A MX2016003871A MX373466B MX 373466 B MX373466 B MX 373466B MX 2016003871 A MX2016003871 A MX 2016003871A MX 2016003871 A MX2016003871 A MX 2016003871A MX 373466 B MX373466 B MX 373466B
Authority
MX
Mexico
Prior art keywords
compositions
proteins
coagulation factor
human recombinant
heterogeneous populations
Prior art date
Application number
MX2016003871A
Other languages
English (en)
Spanish (es)
Other versions
MX2016003871A (es
Inventor
Jason C Rouse
Keith A Johnson
Mary Beth Switzer
Michael Anthony Jankowski
Michael Shamashkin
Penelope Jane Sharpe
Stacey B Weston
Wendy Carol Piacenza
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2016003871A publication Critical patent/MX2016003871A/es
Publication of MX373466B publication Critical patent/MX373466B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4846Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6432Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Water Supply & Treatment (AREA)
  • Toxicology (AREA)
MX2016003871A 2013-09-24 2014-09-16 Composiciones que comprenden poblaciones heterogeneas de proteinas recombinantes humanas de factor xa de coagulacion. MX373466B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361881834P 2013-09-24 2013-09-24
PCT/IB2014/064564 WO2015044836A1 (en) 2013-09-24 2014-09-16 Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins

Publications (2)

Publication Number Publication Date
MX2016003871A MX2016003871A (es) 2016-08-04
MX373466B true MX373466B (es) 2020-05-25

Family

ID=51844797

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016003871A MX373466B (es) 2013-09-24 2014-09-16 Composiciones que comprenden poblaciones heterogeneas de proteinas recombinantes humanas de factor xa de coagulacion.

Country Status (19)

Country Link
US (3) US9757434B2 (enExample)
EP (1) EP3049434A1 (enExample)
JP (1) JP6429885B2 (enExample)
KR (1) KR101988705B1 (enExample)
CN (2) CN105579468A (enExample)
AR (1) AR097732A1 (enExample)
AU (1) AU2014326257B2 (enExample)
BR (1) BR112016005899A8 (enExample)
CA (1) CA2924981C (enExample)
HK (1) HK1218760A1 (enExample)
IL (2) IL244258A0 (enExample)
MX (1) MX373466B (enExample)
MY (1) MY173548A (enExample)
PE (1) PE20160877A1 (enExample)
RU (1) RU2648144C2 (enExample)
SA (1) SA516370751B1 (enExample)
SG (1) SG11201601221XA (enExample)
TW (1) TWI631134B (enExample)
WO (1) WO2015044836A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150103205A (ko) 2013-01-31 2015-09-09 화이자 인코포레이티드 인자 Xa 억제를 길항하기 위한 조성물 및 방법
SG11201601221XA (en) 2013-09-24 2016-04-28 Pfizer Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins
EP4588932A3 (en) * 2016-06-17 2025-10-01 Alexion Pharmaceuticals, Inc. Preparation of factor xa derivatives
EP3722418A1 (en) * 2019-04-08 2020-10-14 AB Enzymes Oy Solution stable enzyme composition

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597799A (en) 1990-09-04 1997-01-28 Cor Therapeutics, Inc. Recombinant agents affecting thrombosis
AT405517B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-deletionsmutanten und analoge davon
AT405516B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-analoge mit modifizierter proteasespaltstelle
AT410216B (de) 1999-08-10 2003-03-25 Baxter Ag Faktor x-analogon mit verbesserter aktivierbarkeit
US20040102388A1 (en) 2000-03-22 2004-05-27 High Katherine A. Modified blood clotting factors and methods of use
FR2831170B1 (fr) 2001-10-19 2004-03-19 Inst Nat Sante Rech Med Proteines c modifiees activables directement par la thrombine
FR2841904B1 (fr) 2002-07-03 2004-08-20 Inst Nat Sante Rech Med Analogues de facteurs x clivables par la thrombine
BRPI0514396A2 (pt) * 2004-08-17 2009-05-12 Csl Behring Gmbh polipeptìdeos dependentes de vitamina k modificada
EP1728798A1 (en) 2005-06-01 2006-12-06 ZLB Behring GmbH Coagulation factor X polypeptides with modified activation properties
MX336958B (es) 2005-11-15 2016-02-05 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
EP1820508A1 (en) 2006-02-21 2007-08-22 CSL Behring GmbH Coagulation factor X polypeptides with modified activation properties
EP2193196B1 (en) * 2007-09-28 2016-07-13 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
PL2300497T3 (pl) 2008-06-24 2013-02-28 Octapharma Ag Sposób oczyszczania czynnika krzepnięcia VIII
EP2364165B1 (en) 2008-11-14 2018-01-03 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents
ES2629099T3 (es) 2008-12-19 2017-08-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Derivados de serin proteasa y usos en la prevención o el tratamiento de y trastornos de la coagulación sanguinea
JP6163304B2 (ja) 2009-07-15 2017-07-12 ポートラ ファーマシューティカルズ, インコーポレイテッド 第Xa因子インヒビターの解毒剤の単位用量処方物およびその使用方法
HRP20191305T1 (hr) * 2010-07-09 2019-10-18 Bioverativ Therapeutics Inc. Preradive jednolančane molekule i polipeptidi izrađeni koristeći iste
FR2972114B1 (fr) 2011-03-01 2013-03-15 Univ Grenoble 1 Un nouveau leurre moleculaire procoagulant pour le traitement des hemophiles a ou b avec ou sans inhibiteur
US9371522B2 (en) 2011-09-30 2016-06-21 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis
SG11201500579SA (en) 2012-07-25 2015-02-27 Catalyst Biosciences Inc Modified factor x polypeptides and uses thereof
KR20150103205A (ko) 2013-01-31 2015-09-09 화이자 인코포레이티드 인자 Xa 억제를 길항하기 위한 조성물 및 방법
SG11201601221XA (en) 2013-09-24 2016-04-28 Pfizer Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins
CA2928762A1 (en) 2013-11-01 2015-05-07 The Children's Hospital Of Philadelphia Compositions and methods for increasing the half-life of factor xa
CA2937418A1 (en) 2014-01-24 2015-07-30 Pfizer Inc. Compositions and methods for treating intracerebral hemorrhage

Also Published As

Publication number Publication date
BR112016005899A8 (pt) 2018-02-06
US20170333535A1 (en) 2017-11-23
EP3049434A1 (en) 2016-08-03
US20150182604A1 (en) 2015-07-02
US9757434B2 (en) 2017-09-12
MX2016003871A (es) 2016-08-04
MY173548A (en) 2020-02-04
US20210106658A1 (en) 2021-04-15
IL244258A0 (en) 2016-04-21
AR097732A1 (es) 2016-04-13
TWI631134B (zh) 2018-08-01
CN105579468A (zh) 2016-05-11
AU2014326257A1 (en) 2016-03-10
BR112016005899A2 (pt) 2017-09-26
CA2924981A1 (en) 2015-04-02
KR20160044034A (ko) 2016-04-22
SG11201601221XA (en) 2016-04-28
RU2648144C2 (ru) 2018-03-22
CA2924981C (en) 2020-03-31
SA516370751B1 (ar) 2018-04-05
JP6429885B2 (ja) 2018-11-28
JP2016535071A (ja) 2016-11-10
IL279396A (en) 2021-01-31
US10660946B2 (en) 2020-05-26
KR101988705B1 (ko) 2019-06-12
PE20160877A1 (es) 2016-09-11
WO2015044836A1 (en) 2015-04-02
RU2016108608A (ru) 2017-10-26
AU2014326257B2 (en) 2017-08-10
TW201524996A (zh) 2015-07-01
CN112195169A (zh) 2021-01-08
HK1218760A1 (zh) 2017-03-10

Similar Documents

Publication Publication Date Title
CY1124436T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
CY1126072T1 (el) Περιοχες gla ως θεραπευτικοι παραγοντες
BR302013006822S1 (pt) Configuração aplicada em curativo médico.
IL255119B (en) Therapeutic pooled blood apoptotic cell preparations and uses thereof
EA201491856A1 (ru) Терапевтическое применение белков фактора роста фибробластов 21
MX2020000083A (es) Factor de von willebrand recombinante ( rvwf ) y factor viii recombinante ( rfviii ) para usarse en un metodo para tratar la enfermedad de von willebrand.
EP2988771A4 (en) FIBRINOGENIC FABRIC PADS
EP2889308A4 (en) CONEPOXIN PEPTIDE OF THE ALPHA O-SUPERFAMILY, PHARMACEUTICAL COMPOSITION AND USE THEREOF
IL242137B (en) Methods and compositions for wound healing
EP2974751A4 (en) HEART OR TISSUE SPHERE
IL279396A (en) Preparations containing heterogeneous populations of recombinant human coagulation factor XA proteins
EA201390955A1 (ru) Слитый белок robo1-fc для применения в лечении гепатокарциномы
EP3359962A4 (en) BLOOD PREPARATION AND PROFILING
UA117933C2 (uk) Поліпептид, здатний зв'язувати с5-компонент комплементу людини
MX387579B (es) Polipéptidos del factor vii de acción corta.
MX2016004702A (es) Polipeptidos del factor vii de coagulacion.
PL2904009T3 (pl) Związki do leczenia blokady mielinizacji w chorobach związanych z ekspresją białka otoczki herv-w
EP3752113C0 (en) SURGICAL GAUZE
EA201692161A1 (ru) Прогемостатические белки для лечения кровотечений
WO2013109190A3 (en) Cho-gmt recombinant protein expression
BR112014018709A8 (pt) Composições e efetores de beta-arrestina e métodos de uso dos mesmos
PH12016500509A1 (en) Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins
MX2015007625A (es) Composiciones sellantes.
MX385558B (es) Péptidos y métodos de uso.
TH1501000355A (th) วิธีผลิตสารองค์ประกอบเพปไทด์คอลลาเจน สารกด dpp-4 และสารยับยั้งการเพิ่มสูงขึ้นของค่าน้ำตาลในเลือด

Legal Events

Date Code Title Description
FG Grant or registration